Oramed Pharmaceuticals (ORMP)
(Delayed Data from NSDQ)
$2.35 USD
-0.06 (-2.49%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $2.35 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Oramed Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 3 | 1 | 3 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 3 | 1 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 17 | 43 | 13 | 27 | 14 |
Income After Depreciation & Amortization | -16 | -41 | -12 | -24 | -12 |
Non-Operating Income | 23 | 4 | 0 | 1 | 1 |
Interest Expense | 2 | 1 | 0 | 0 | 0 |
Pretax Income | 5 | -38 | -12 | -23 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | -1 | -1 | -1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 5 | -38 | -12 | -23 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 6 | -37 | -12 | -22 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -41 | -12 | -24 | -12 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -16 | -41 | -12 | -24 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 40.57 | 39.00 | 28.47 | 20.53 | 17.46 |
Diluted EPS Before Non-Recurring Items | -0.27 | -0.94 | -0.78 | -0.56 | 0.82 |
Diluted Net EPS (GAAP) | 0.14 | -0.94 | -0.78 | -0.78 | -0.56 |
Fiscal Year end for Oramed Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.67 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.67 |
SG&A, R&D, and Dept/Amort Expenses | 3.13 | 2.96 | 3.88 | 2.90 | 4.46 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.13 | -2.96 | -3.88 | -2.90 | -3.79 |
Non-Operating Income | 14.23 | 5.09 | 18.38 | 0.44 | 2.48 |
Interest Expense | 0.26 | 0.59 | 1.21 | 0.83 | 0.00 |
Pretax Income | 10.84 | 1.53 | 13.30 | -3.28 | -1.31 |
Income Taxes | 1.63 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | -0.01 | 0.00 | -0.26 | -0.06 | -0.12 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 9.20 | 1.53 | 13.30 | -3.28 | -1.31 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 9.21 | 1.53 | 13.55 | -3.22 | -1.19 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 41.59 | 41.56 | 40.41 | 40.45 | 40.23 |
Diluted EPS Before Non-Recurring Items | 0.22 | 0.04 | -0.08 | -0.08 | -0.03 |
Diluted Net EPS (GAAP) | 0.22 | 0.04 | 0.33 | -0.08 | -0.03 |